• ENGLISH
  • ESPAÑOL
facebook
twitter
  • National>Entertainment
  • National>Local Economics
  • National>Local Politics
  • National>Society
  • National>Sports
BREAKING NEWS
Almost half of the rural population lives on less than USD 2.80 a day
The unemployment rate for women increased from 5.7% to 7.4% between 2019 and 2020
In one year, more than 650,000 people lost their jobs; index would recover in four years, according to experts
Information technology (ICT) reduced the digital divide in the country
Fishing sector rejects proposal to expand the Galapagos marine reserve
Municipality of Guayaquil announces that it will acquire the Russian vaccine Sputnik V, the Chinese Sinovac and the Oxford doses
Flights in Ecuador fail to recover the frequencies of before the pandemic
Achievements of digital transformation are exposed in “A Digitized Country, A Modern Country”
Yaku Pérez: ‘I am not a supporter of violence; I am adept of a resistance ‘
If the bill for the Defense of Dollarization in Ecuador is not approved, the next IMF disbursement of $ 450 million would be put on hold

Pharmaceutical company tests “successful” experimental vaccine against Ebola

Posted On 25 Aug 2014

Ebola-Vacuna-experimental-Immunovaccine-Canada

Four monkeys received today an experimental vaccine against Ebola, developed by the Canadian pharmaceutical Immunovaccine, and survived after being exposed to a lethal dose of the virus.

Immunovaccine added that two monkeys which were exposed to Ebola but not did not receive the experimental vaccine died. The animals used in the experiment were cynomolgus monkeys.

The company said in a statement that the surviving macaques received two doses of the vaccine before being exposed to a “lethal dose” of the Zaire strain of Ebola, “considered the most lethal Ebola virus responsible for the current outbreak” in Africa.

“Given the high efficiency observed in macaques, Immunovaccine is exploring a potential program development of a Ebola virus vaccine with various organizations,” the company added.

The executive director of Immunovaccine, Marc Mansour, said: “These preliminary results are encouraging and support the continuous assessment of a Ebola vaccine in DepoVax (developer company)”.

 

About the Author
  • google-share
Previous Story

Ernesto Samper will become general secretary of UNASUR

Next Story

Hurricane Marie weakens to category three and keeps moving

SEARCH

LATEST NEWS

Almost half of the rural population lives on less than USD 2.80 a day

Posted On 04 Mar 2021

The unemployment rate for women increased from 5.7% to 7.4% between 2019 and 2020

Posted On 04 Mar 2021

In one year, more than 650,000 people lost their jobs; index would recover in four years, according to experts

Posted On 04 Mar 2021
Copyright © 2010 - 2019. All Rights Reserved. EcuadorTimes.net